Loading...
Back to narrative

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

YPSN logo
YPSN
AnalystConsensusTarget
Not Invested
Published 07 Dec 2024

Update shared on05 Sep 2025

Fair value Increased 1.69%
Previous
AnalystConsensusTarget's Fair Value
CHF 463.26
11.5% undervalued intrinsic discount
05 Sep
CHF 410.00
Loading
1Y
-3.1%
7D
2.0%

Ypsomed Holding’s analyst price target has been revised upward to CHF463.26 as the company consolidates its leadership in the high-growth injectables market following strategic divestitures and a sharpened operational focus.


Analyst Commentary


  • The company has established a leadership position in the high-growth injectable market.
  • Ypsomed has transitioned into a pure-play injectables company through four strategic divestitures.
  • The restructuring away from a diabetes conglomerate is expected to sharpen business focus and improve operational efficiency.
  • The injectables market is experiencing unprecedented demand, benefiting Ypsomed's core business.
  • Bullish analysts see these factors supporting significant upside potential in the company’s share price.

What's in the News


  • Held an Analyst/Investor Day event.

Valuation Changes


Summary of Valuation Changes for Ypsomed Holding

  • The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from CHF455.54 to CHF463.26.
  • The Future P/E for Ypsomed Holding has risen slightly from 27.27x to 27.91x.
  • The Consensus Revenue Growth forecasts for Ypsomed Holding remained effectively unchanged, moving only marginally from 6.8% per annum to 6.7% per annum.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.